Distinct PGE2-responder and non-responder phenotypes in human mast cell populations: "All or nothing" enhancement of antigen-dependent mediator release

Immunology Letters

Volumn 141, Issue 1, 2011, Pages 45-54

  Kuehn, Hye Sun ^a   Jung, Mi Yeon ^a   Beaven, Michael A ^b   Metcalfe, Dean D ^a   Gilfillan, Alasdair M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cytokine release; Degranulation; Mast cells; PGE2; Signaling

Indexed keywords

ANTIGEN; BUTAPROST; CALCIUM; CYCLIC AMP; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; SULPROSTONE; DRUG DERIVATIVE; PHOSPHOLIPASE C GAMMA; PROSTAGLANDIN E1;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CALCIUM SIGNALING; CELL ACTIVATION; CELL MEMBRANE; CELL POPULATION; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; ANIMAL; C57BL MOUSE; CELL LINE; DEGRANULATION; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SECRETION; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE;

ALPROSTADIL; ANIMALS; CELL DEGRANULATION; CELL LINE; DINOPROSTONE; HUMANS; INTERLEUKIN-8; MAST CELLS; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOLIPASE C GAMMA; PROTEIN TRANSPORT; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 80955163718     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.07.002     Document Type: Article

References (32)

1. Metcalfe D.D., Baram D., Mekori Y.A. Mast cells. Physiol Rev 1997, 77:1033-1079.
2. Kraft S., Kinet J.P. New developments in Fce{open}RI regulation, function and inhibition. Nat Rev Immunol 2007, 7:365-378.
3. Gilfillan A.M., Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006, 6:218-230.
4. Rivera J., Gilfillan A.M. Molecular regulation of mast cell activation. J Allergy Clin Immunol 2006, 117:1214-1225. quiz 1226.
5. Metcalfe D.D., Peavy R.D., Gilfillan A.M. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 2009, 124:639-646. quiz 647-638.
6. Hundley T.R., Gilfillan A.M., Tkaczyk C., Andrade M.V., Metcalfe D.D., Beaven M.A. Kit and Fce{open}RI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood 2004, 104:2410-2417.
7. Tkaczyk C., Horejsi V., Iwaki S., Draber P., Samelson L.E., Satterthwaite A.B., et al. NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fce{open}RI aggregation. Blood 2004, 104:207-214.
8. Qiao H., Andrade M.V., Lisboa F.A., Morgan K., Beaven M.A. Fce{open}R1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood 2006, 107:610-618.
9. Drube S., Heink S., Walter S., Lohn T., Grusser M., Gerbaulet A., et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010, 115:3899-3906.
10. Kuehn H.S., Gilfillan A.M. G protein-coupled receptors and the modification of Fce{open}RI-mediated mast cell activation. Immunol Lett 2007, 113:59-69.
11. Ali H. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett 2009, 128:36-45.
12. Forsythe P., Ennis M. Adenosine, mast cells and asthma. Inflamm Res 1999, 48:301-307.
13. Jensen B.M., Metcalfe D.D., Gilfillan A.M. Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation. Inflamm Allergy Drug Targets 2007, 6:57-62.
14. Beaven M.A. Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol 2009, 39:11-25.
15. Iwaki S., Tkaczyk C., Satterthwaite A.B., Halcomb K., Beaven M.A., Metcalfe D.D., et al. Btk plays a crucial role in the amplification of Fce{open}RI-mediated mast cell activation by kit. J Biol Chem 2005, 280:40261-40270.
16. Ali K., Bilancio A., Thomas M., Pearce W., Gilfillan A.M., Tkaczyk C., et al. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 2004, 431:1007-1011.
17. Iwaki S., Spicka J., Tkaczyk C., Jensen B.M., Furumoto Y., Charles N., et al. Kit-Fce{open}RI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells. Cell Signal 2008, 20:195-205.
18. Pushparaj P.N., Tay H.K., H'Ng S.C., Pitman N., Xu D., McKenzie A., et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009, 106:9773-9778.
19. O'Neill L.A., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364.
20. Kuehn H.S., Beaven M.A., Ma H.T., Kim M.S., Metcalfe D.D., Gilfillan A.M. Synergistic activation of phospholipases Cγ and Cβ: a novel mechanism for PI3K-independent enhancement of Fce{open}RI-induced mast cell mediator release. Cell Signal 2008, 20:625-636.
21. 2-mediated regulation of mast cell degranulation and IL-6 production. J Immunol 2002, 169:4586-4593.
22. 2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism. J Immunol 2000, 165:6545-6552.
23. 2 that differentially modulate activation responses. Blood 2006, 107:3243-3250.
24. 2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol 2006, 147:707-713.
25. 1-dependent pathway of Fce{open}RI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J Biol Chem 2003, 278:48474-48484.
26. Kirshenbaum A.S., Goff J.P., Semere T., Foster B., Scott L.M., Metcalfe D.D. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999, 94:2333-2342.
27. Kirshenbaum A.S., Akin C., Wu Y., Rottem M., Goff J.P., Beaven M.A., et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of Fce{open}RI or FcγRI. Leuk Res 2003, 27:677-682.
28. Tkaczyk C., Metcalfe D.D., Gilfillan A.M. Determination of protein phosphorylation in Fce{open}RI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. J Immunol Methods 2002, 268:239-243.
29. Kuehn H.S., Radinger M., Brown J.M., Ali K., Vanhaesebroeck B., Beaven M.A., et al. Btk-dependent Rac activation and actin rearrangement following Fce{open}RI aggregation promotes enhanced mast cell chemotactic responses. J Cell Sci 2010, 123:2576-2585.
30. 2) receptor agonists as therapeutic agents for the treatment of asthma. Sci STKE 2005, pe47.
31. Gilfillan A.M., Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009, 228:149-169.
32. Okayama Y., Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006, 34:97-115.